Regeneron Pharmaceuticals, Inc.
Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –
Regeneron Pharmaceuticals Evkeeza by Quarter
Evkeeza — U.S. Net Product Sales Recorded by Regeneron ($M) ($M)
Regeneron Pharmaceuticals Evkeeza: $55.5M in Q3 2026, up 29.7% from a year earlier. That is the highest of the 27 quarters on record here.
Where the Q3 2026 figure comes from
Source: Form 10-Q (filed 2026-10-30) ↗
Reported in Form 10-Q / 10-K Note — Net Product Sales (XBRL).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Evkeeza — U.S. Net Product Sales Recorded by Regeneron ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 55.5 | +29.7% | Form 10-Q (filed 2026-10-30) ↗ |
| Q2 2026 | Jun 30, 2026 | 53.3 | +29.4% | Form 10-Q (filed 2026-07-30) ↗ |
| Q1 2026 | Mar 31, 2026 | 45.7 | +47.9% | Form 10-Q (filed 2026-04-29) ↗ |
| Q4 2025 | Dec 31, 2025 | 47.3 | +24.1% | Form 10-K (filed 2026-02-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 42.8 | +32.1% | Form 10-Q (filed 2026-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 41.2 | +35.5% | Form 10-Q (filed 2026-07-30) ↗ |
| Q1 2025 | Mar 31, 2025 | 30.9 | +24.6% | Form 10-Q (filed 2026-04-29) ↗ |
| Q4 2024 | Dec 31, 2024 | 38.1 | +58.8% | Form 10-K (filed 2026-02-04) ↗ |
| Q3 2024 | Sep 30, 2024 | 32.4 | +69.6% | Form 10-Q (filed 2025-10-28) ↗ |
| Q2 2024 | Jun 30, 2024 | 30.4 | +57.5% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 24.8 | +66.4% | Form 10-Q (filed 2025-04-29) ↗ |
| Q4 2023 | Dec 31, 2023 | 24 | +55.8% | Form 10-K (filed 2026-02-04) ↗ |
| Q3 2023 | Sep 30, 2023 | 19.1 | +40.4% | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 19.3 | +73.9% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2023 | Mar 31, 2023 | 14.9 | +75.3% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 15.4 | +65.6% | Form 10-K (filed 2025-02-05) ↗ |
| Q3 2022 | Sep 30, 2022 | 13.6 | +106.1% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 11.1 | +455.0% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 8.50 | +1,600.0% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 9.30 | – | Form 10-K (filed 2024-02-05) ↗ |
| Q3 2021 | Sep 30, 2021 | 6.60 | – | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 2 | – | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2021 | Mar 31, 2021 | 0.50 | – | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2020 | Dec 31, 2020 | 0 | – | Form 10-K (filed 2023-02-06) ↗ |
| Q3 2020 | Sep 30, 2020 | 0 | – | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 0 | – | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 0 | – | Form 10-Q (filed 2021-05-06) ↗ |
Breakdown
What makes up evkeeza
Cite this data
StockData. (2026). Regeneron Pharmaceuticals Evkeeza ($M), quarterly Q1 2020–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rev-evkeeza-us
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?